Amneal Pharmaceuticals
AMRX
133 hedge funds and large institutions have $455M invested in Amneal Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 23 funds opening new positions, 38 increasing their positions, 43 reducing their positions, and 29 closing their positions.
79% more call options, than puts
Call options by funds: $1.93M | Put options by funds: $1.08M
15% more capital invested
Capital invested by funds: $394M → $455M (+$60.8M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
1.4% less ownership
Funds ownership: 68.79% → 67.39% (-1.4%)
5% less funds holding
Funds holding: 140 → 133 (-7)
12% less repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 43
21% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MF
Magnetar Financial
Evanston,
Illinois
|
+$2.45M |
| 2 |
JP Morgan Chase
New York
|
+$2M |
| 3 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$1.84M |
| 4 |
Goldman Sachs
New York
|
+$1.7M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$1.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$6.67M |
| 2 |
EP
Eversept Partners
New York
|
-$6.55M |
| 3 |
BlackRock
New York
|
-$4.07M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$1.99M |
| 5 |
Bank of New York Mellon
New York
|
-$989K |
AMRX Hedge Fund Activity: Q4 2020 in Review
133 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Amneal Pharmaceuticals (AMRX) for Q4 2020, worth a combined $455M — up 15% from $394M a quarter earlier.
Sellers outnumbered buyers: 29 funds closed out of AMRX and 23 opened new positions — a net loss of 6 holders — while 43 trimmed existing stakes and 38 added.
The largest buyer was Magnetar Financial, opening a new position worth an estimated $2.45M. The largest seller was Wellington Management Group, cutting an estimated $6.67M.
- 133 institutional investors held Amneal Pharmaceuticals (AMRX) as of Q4 2020, down from 140 in Q3 2020.
- Funds reported $455M of Amneal Pharmaceuticals stock for Q4 2020, up 15% quarter-over-quarter.
- 23 funds opened new Amneal Pharmaceuticals positions in Q4 2020 and 29 closed out, a net change of -6 holders.
- The largest Amneal Pharmaceuticals buyer in Q4 2020 was Magnetar Financial, an estimated $2.45M added.
- The largest Amneal Pharmaceuticals seller in Q4 2020 was Wellington Management Group, an estimated $6.67M sold.
Based on aggregated 13F filings for Q4 2020.